BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 29, 2026
Breaking News: Science fiction realized: BCI tech is hereBreaking News: FDA says yes to Viridian’s Lumvoa in TEDBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Cancer

Artios Pharma patents POLQ inhibitors for cancer

May 11, 2023
Recent Artios Pharma Ltd. patents describe DNA polymerase θ (POLQ) inhibitors which are...
Read More
Natural killer cell attacking cancer cell
Cancer

ZW-270, a masked IL-12 fusion protein, shows superior antitumor efficacy in preclinical studies

May 11, 2023
Interleukin-12 (IL-12) is a pleiotropic cytokine designated as a cytotoxic lymphocyte maturation factor and NK cell stimulator that interconnects innate and adaptive immunity. Studies in animal models have shown antitumor effects, but its translation into the clinic has been often linked to unacceptable toxicity.
Read More
Cancer

AXL/FLT3 inhibitor from Cytosinlab Therapeutics has activity in AML/MDS and lung cancer models

May 11, 2023
It was previously shown that AXL overexpression is associated with poor prognosis, metastasis, as well as drug resistance in various hematological and solid tumors, and that inhibition of AXL phosphorylation could overcome drug resistance to FLT3 inhibitors. CTS-2016 is an AXL/FLT3 inhibitor being developed by Cytosinlab Therapeutics Co. Ltd. as a novel tyrosine kinase inhibitor for cancer.
Read More
3D representation of tumor microenvironment
Cancer

TY-0540 demonstrates activity in different tumor models, including palbociclib-resistant models

May 11, 2023
Researchers from TYK Medicines Inc. presented the discovery and preclinical evaluation of a new cyclin-dependent kinase 274/6 (CDK2/4/6) inhibitor, TY-0540, being developed as an anticancer agent.
Read More
Immuno-oncology

Simcere Pharma provides preclinical data on SCR-8572 antibody for treating multiple myeloma

May 11, 2023
Simcere Pharmaceutical Group recently reported preclinical data on the dual BCMA/GPRC5D...
Read More
Microscope with laptop displaying histology image.
Cancer

ClpP agonist TR-107 inhibits cancer growth both in vitro and in vivo

May 11, 2023
TR-107 is a new oral ClpP agonist that targets the ClpX complex, which is responsible for the...
Read More
Musculoskeletal

Study identifies cachexia signaling axis in muscle

May 11, 2023
By Anette Breindl
Blocking signaling through the ectodysplasin A2 receptor (EDA2R), a member of the TNF receptor family, protected tumor-bearing mice from developing muscle atrophy associated with cancer cachexia. Upstream and downstream of EDA2R, “we identified two distinct pathways and we demonstrated their involvement in muscle wasting,” Serkan Kir told BioWorld. Kir is a professor at the Koç University Center for Translational Medicine and corresponding author of the paper reporting the findings, which appeared in Nature on May 10, 2023.
Read More
Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.
Cancer

HC-5404 improves response to VEGFR-TKIs and ICIs in preclinical models

May 10, 2023
Researchers from Hibercell Inc. presented preclinical data for the eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitor HC-5404, currently in phase I development for the treatment of solid tumors (NCT04834778).
Read More
Cancer

Sunshine Lake Pharma divulges KRAS G12D inhibitors for treatment of cancer

May 10, 2023
Pyrimidopyridine derivatives acting as GTPase KRAS G12D inhibitors have been reported in a Sunshine Lake Pharma Co. Ltd. patent as potentially useful for the treatment of cancer.
Read More
Cancer

Beijing Tide Pharmaceutical reports development of PROTACs

May 10, 2023
Beijing Tide Pharmaceutical Co. Ltd. has prepared proteolysis-targeting chimera (PROTAC) compounds comprising an ubiquitin ligase binding moiety bound to a protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety through a linker.
Read More
Previous 1 2 … 484 485 486 487 488 489 490 491 492 … 3709 3710 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • Cortec Brain Interchange BCI system

    Brain-computer interfaces are here but long road ahead

    BioWorld
    The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
  • Subsense BCI platform

    Next wave of BCI firms builds on pioneers to tackle challenges

    BioWorld
    With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
  • Boehringer Ingelheim identifies new mGlu3 receptor agonists

    BioWorld Science
    Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing